Navigation Links
Japan Patent Office Licenses GeneCards(R) from Xennex, Inc.
Date:5/5/2008

Xennex, Inc. Partners with Bioscene in Japan - Expands Presence in Japan

CAMBRIDGE, Mass., May 5 /PRNewswire/ -- Xennex, Inc. (Xennex) announced today that the Japan Patent Office (JPO) has licensed GeneCards(R). Xennex also announced that it has selected Bioscene Informatics Inc. (Bioscene) as its exclusive partner for the distribution of GeneCards in Japan.

GeneCards will be utilized to assist the JPO in the review and approval of patent applications in the life sciences area. With this agreement, GeneCards becomes an important component in the process of approving relevant biotech patent applications at the JPO. Patent examiners from the JPO will access GeneCards to conduct prior art research and help determine if an invention can be patented. The European Patent Office (EPO) has been using GeneCards under a license from Xennex since 2005.

Dr. David Warshawsky, CEO of Xennex, stated: "We are very pleased that the JPO has chosen GeneCards to assist in their work. GeneCards is a very useful tool for professionals dealing with intellectual property in the life sciences area, including biotech, pharma, and intellectual property law firms. The EPO has been using GeneCards very successfully for several years now; with the JPO's licensing of GeneCards, we continue to expand our presence in the intellectual property field. We believe that as the worldwide intellectual property arena expands and nations increase their cooperation on intellectual property issues, GeneCards will have an important and lasting contribution to the uniformity required for this cooperative process."

In addition to the intellectual property field, GeneCards is widely used by hundreds of commercial and academic organizations by thousands of users around the globe, including, academic researchers, as well as R&D groups in biotechnology and pharmaceutical companies.

GeneCards is widely used in Japan, by academic researchers and by several of the world's leadin
'/>"/>

SOURCE Xennex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medinet Licenses MaxCyte Cell Loading Technology for Cancer Immunotherapy in Japan
2. Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
3. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
6. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
7. NPS Pharmaceuticals Announces Approval of Cinacalcet HCl in Japan
8. Neurocrine Biosciences and Dainippon Sumitomo Pharma (DSP) Announce Agreement to Develop and Commercialize Indiplon in Japan
9. Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan
10. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
11. American Scientists Named as Laureates of the 2008 (24th) Japan Prize
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2015)... ... June 26, 2015 , ... Charm ... Grain Inspection, Packers and Stockyards Administration (GIPSA) awarded a five year contract to ... and grains utilizing Charm’s ROSA DONQ-FAST5 Test. This 5 minute quantitative test extracts ...
(Date:6/26/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/w48l6t/global_cancer ... "Global Cancer Biosimilars Market Opportunity Outlook" report ... cancer biosimilar is required because they have both ... dominated the cancer segment for several decade but ... few years. They are biologic in origin and ...
(Date:6/25/2015)... Last June, a dedicated global team of Ebola researchers began ... sequencing. Their research, which was written on the research platform ... (Park 2015) , reveals critical information about how ... recent Ebola outbreak. Today Authorea is pleased to ... edit history of the paper are available to the ...
(Date:6/25/2015)... ... June 25, 2015 , ... Students entering the new Hemenway ... laboratories, each exclusively using filtered fume hoods that feature Erlab’s GreenFumeHood Filtration ... fume hoods needed for their Organic, Inorganic, Analytical, and Physical Chemistry teaching laboratories. ...
Breaking Biology Technology:USDA-GIPSA (FGIS) Awards 5 Year Contract for Vomitoxin Tests to Charm Sciences 2Global Cancer Biosimilars Market Opportunity Outlook 2Global Cancer Biosimilars Market Opportunity Outlook 3Open Science Takes Major Leap Forward 2This Summer Erlab Completes the Largest Installation of Filtered Fume Hoods in the World 2
... Companies will Present at the Largest Marketplace for Emerging ... and CTSI today announced that more than 100 leading ... partners will be showcased in the 4th Annual TechConnect ... R. Brown Convention Center in Houston, Texas. Held ...
... Development and InnovationMOUNTAIN VIEW, Calif., April 22 ... Pharmaceuticals & Biotechnology group assesses a variety of ... in cancer treatment. Physicians, nurses and patients ... reconstitution, home vs. office administration parameters, and barriers ...
... 22 GeneGo, Inc., a leading provider of software ... , today announced that the University of Cardiff has ... researchers will have access to GeneGo,s MetaCore, training and ... their partner relationship with GeneGo to provide a pathway ...
Cached Biology Technology:TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 2TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 3TechConnect Summit Brings the Global Technology Community to Houston, May 4-6, 2009 4Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 2Frost & Sullivan: Female Cancer Patients More Willing to Use Implantable Infusion Pumps Than Males 3Cardiff University Becomes a GeneGo Center of Excellence 2
(Date:6/25/2015)... N.J. , June 25, 2015  TAKE Solutions ... a patent by the United States Patent and Trademark ... Standardization". This process leverages TAKE Solutions, Clinical Accelerators to ... over 50% (when compared to standardization without the accelerators), ... At the heart of ...
(Date:6/24/2015)... 2015 This report provides market analysis of ... years. It contains an analysis of the drivers, challenges, ... impact from the short, medium, and long term perspective ... market, and technology trends that currently, prevail in the ... authorities to efficiently manage the increasing marine traffic and ...
(Date:6/24/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/hhwlfj/huawei_ascend ... "Huawei Ascend Mate 7 Fingerprint Sensor - Reverse ... Huawei,s technological choice for the fingerprint sensor ... and Samsung,s one. The Ascend Mate 7 presents ... a main actor in capacitive sensing human interface ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... Jos Zanchetta, a member of the IOF Board and ... has been named the recipient of the prestigious Pierre ... Osteoporosis Foundation (IOF) in memory of Pierre D. Delmas, ... growth of the Foundation and osteoporosis advocacy worldwide. ...
... the damage caused by a heart attack survived in the ... a mouse model, researchers at The University of Texas MD ... Circulation Research . The study, with researchers at the ... imaging techniques developed by researchers at MD Anderson to track ...
... a 1600 km-wide ash cloud over the Atlantic. The ... visible in stark contrast to white clouds framing this ... emitting steam and ash on 20 March, wreaking havoc ... week caused some flights to be suspended to and ...
Cached Biology News:Transplanted adult stem cells provide lasting help to injured hearts 2Transplanted adult stem cells provide lasting help to injured hearts 3Transplanted adult stem cells provide lasting help to injured hearts 4
...
cysteine and glycine-rich protein 2,...
... agent and DNA-topoisomersae II inhibitor (IC50 = 59.2 ... C 29 H 32 O 13 ... Store at: RT ... Soluble to 100 mM ...
HSPBP1 Antibody...
Biology Products: